[{"id":"742fd153-ce97-4ee4-b30a-065c666ab97f","acronym":"UNICORN","url":"https://clinicaltrials.gov/study/NCT05845450","created_at":"2023-05-06T15:04:38.828Z","updated_at":"2025-02-25T14:09:41.563Z","phase":"Phase 2","brief_title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","source_id_and_acronym":"NCT05845450 - UNICORN","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","biomarkers":" HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1","pipe":" | ","alterations":" HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type","tags":["HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 05/11/2023","start_date":" 05/11/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-02-17"},{"id":"256df84b-62ee-44dd-bf61-7e052e3333ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT02899793","created_at":"2021-01-18T14:13:54.458Z","updated_at":"2025-02-25T16:05:12.956Z","phase":"Phase 2","brief_title":"Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer","source_id_and_acronym":"NCT02899793","lead_sponsor":"Yale University","biomarkers":" MSI • POLE • POLD1","pipe":" | ","alterations":" POLE mutation • POLD1 mutation","tags":["MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation • POLD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-01-31"},{"id":"07c7a5d9-df0c-45c5-9b74-abae8c8d1379","acronym":"","url":"https://clinicaltrials.gov/study/NCT03751761","created_at":"2021-01-18T18:23:38.922Z","updated_at":"2024-07-02T16:35:17.456Z","phase":"Phase 1/2","brief_title":"GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study","source_id_and_acronym":"NCT03751761","lead_sponsor":"Asan Medical Center","biomarkers":" PD-L1 • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • PMS1 • POLD2","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PD-L1 amplification • POLD1 mutation • MSH3 mutation • PMS2 mutation • MLH3 mutation • PMS1 mutation • POLD2 mutation","tags":["PD-L1 • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • PMS1 • POLD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PD-L1 amplification • POLD1 mutation • MSH3 mutation • PMS2 mutation • MLH3 mutation • PMS1 mutation • POLD2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 06/11/2018","start_date":" 06/11/2018","primary_txt":" Primary completion: 08/30/2023","primary_completion_date":" 08/30/2023","study_txt":" Completion: 08/30/2023","study_completion_date":" 08/30/2023","last_update_posted":"2024-02-28"},{"id":"44b18821-ce38-48ad-a230-792c3c2069f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03810339","created_at":"2021-01-18T18:49:40.399Z","updated_at":"2024-07-02T16:35:44.660Z","phase":"Phase 2","brief_title":"Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors","source_id_and_acronym":"NCT03810339","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1 • MSI • POLE • POLD1","pipe":" | ","alterations":" POLE mutation • POLD1 mutation","tags":["PD-L1 • MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation • POLD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 01/15/2019","start_date":" 01/15/2019","primary_txt":" Primary completion: 01/15/2024","primary_completion_date":" 01/15/2024","study_txt":" Completion: 01/15/2024","study_completion_date":" 01/15/2024","last_update_posted":"2023-06-27"},{"id":"f3638445-1962-425f-bf99-dd0895925929","acronym":"NCI-2018-00115","url":"https://clinicaltrials.gov/study/NCT03428802","created_at":"2021-01-18T16:54:49.559Z","updated_at":"2024-07-02T16:36:00.195Z","phase":"Phase 2","brief_title":"Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability","source_id_and_acronym":"NCT03428802 - NCI-2018-00115","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" PD-L1 • BRCA1 • BRCA2 • POLE • POLD1","pipe":" | ","alterations":" BRCA1 mutation • POLD1 mutation • POLE mutation + POLD1 mutation","tags":["PD-L1 • BRCA1 • BRCA2 • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • POLD1 mutation • POLE mutation + POLD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/08/2018","start_date":" 03/08/2018","primary_txt":" Primary completion: 10/02/2023","primary_completion_date":" 10/02/2023","study_txt":" Completion: 10/02/2023","study_completion_date":" 10/02/2023","last_update_posted":"2022-11-18"},{"id":"0a5b61b3-7667-454c-b61f-affb10bb9e77","acronym":"3CI Study","url":"https://clinicaltrials.gov/study/NCT04500548","created_at":"2021-01-18T21:33:32.102Z","updated_at":"2024-07-02T16:36:04.140Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study","source_id_and_acronym":"NCT04500548 - 3CI Study","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • POLD1 mutation • PMS2 mutation • EPCAM expression • POLE mutation + POLD1 mutation • MSH6 expression","tags":["TMB • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • POLD1 mutation • PMS2 mutation • EPCAM expression • POLE mutation + POLD1 mutation • MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/28/2021","start_date":" 01/28/2021","primary_txt":" Primary completion: 06/21/2022","primary_completion_date":" 06/21/2022","study_txt":" Completion: 06/21/2022","study_completion_date":" 06/21/2022","last_update_posted":"2022-09-12"},{"id":"0a61150d-21b5-45c1-826c-99d62c159626","acronym":"","url":"https://clinicaltrials.gov/study/NCT03491345","created_at":"2021-01-18T17:11:42.816Z","updated_at":"2025-02-25T16:07:47.926Z","phase":"Phase 2","brief_title":"K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor","source_id_and_acronym":"NCT03491345","lead_sponsor":"Yonsei University","biomarkers":" PD-L1 • MSI • POLE • POLD1","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • POLE mutation • POLD1 mutation","tags":["PD-L1 • MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • POLE mutation • POLD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 08/01/2017","start_date":" 08/01/2017","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-08-09"}]